ERBB2 and breast carcinoma: Together, these results indicate that loss of PRLR expression in HER2-E breast cancer cells causes aberrant luminal and epithelial differentiation state with enhanced HER2 expression/activity and reduced sensitivity to HER2 targeted therapy.